NexImmune, Inc., a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases. It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation, a nanoparticle technology platform. The company's product candidates include NEXI-001, an allogeneic cell therapy, which is in Phase I/II clinical trials for the treatment of patients with acute myeloid leukemia; and NEXI-002, an autologous cell therapy, which is in Phase I/II clinical trials for the treatment of patients with relapsed and/or refractory in multiple myeloma. NexImmune, Inc. was incorporated in 2011 and is headquartered in Gaithersburg, Maryland.
IPO Year: 2021
Exchange: NASDAQ
Website: neximmune.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/22/2022 | $21.00 → $13.00 | Outperform | Raymond James |
| 11/15/2021 | $30.00 → $21.00 | Outperform | Raymond James |